Morgan Stanley
EDIT icon

Morgan Stanley’s Editas Medicine EDIT Stock Holding History

Morgan Stanley’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.11M Sell
342,165
-69,027
-17% -$202K ﹤0.01% 5164
2026
Q1 		$1.02M Sell
411,192
-267,721
-39% -$567K ﹤0.01% 5137
2025
Q4 		$1.39M Sell
678,913
-408,994
-38% -$1.18M ﹤0.01% 5016
2025
Q3 		$3.78M Sell
1,087,907
-332,776
-23% -$929K ﹤0.01% 4366
2025
Q2 		$3.13M Sell
1,420,683
-1,238,238
-47% -$2.03M ﹤0.01% 4417
2025
Q1 		$3.08M Buy
2,658,921
+1,118,298
+73% +$1.65M ﹤0.01% 4306
2024
Q4 		$1.96M Buy
1,540,623
+233,428
+18% +$595K ﹤0.01% 4708
2024
Q3 		$4.46M Buy
1,307,195
+388,961
+42% +$1.69M ﹤0.01% 4046
2024
Q2 		$4.29M Sell
918,234
-865,498
-49% -$4.88M ﹤0.01% 4012
2024
Q1 		$13.2M Buy
1,783,732
+519,197
+41% +$4.31M ﹤0.01% 3108
2023
Q4 		$12.8M Sell
1,264,535
-70,162
-5% -$616K ﹤0.01% 3120
2023
Q3 		$10.4M Sell
1,334,697
-370,261
-22% -$3.18M ﹤0.01% 3095
2023
Q2 		$14M Buy
1,704,958
+828,521
+95% +$7.22M ﹤0.01% 2847
2023
Q1 		$6.35M Sell
876,437
-6,873
-0.8% -$61.1K ﹤0.01% 3574
2022
Q4 		$7.83M Sell
883,310
-22,426
-2% -$246K ﹤0.01% 3312
2022
Q3 		$11.1M Sell
905,736
-164,717
-15% -$2.57M ﹤0.01% 2846
2022
Q2 		$12.7M Sell
1,070,453
-51,317
-5% -$688K ﹤0.01% 2821
2022
Q1 		$21.3M Buy
1,121,770
+155,072
+16% +$2.88M ﹤0.01% 2046
2021
Q4 		$25.7M Buy
966,698
+53,650
+6% +$1.85M ﹤0.01% 1904
2021
Q3 		$37.5M Buy
913,048
+103,589
+13% +$5.68M 0.01% 1502
2021
Q2 		$45.8M Sell
809,459
-156,838
-16% -$5.79M 0.01% 1376
2021
Q1 		$40.6M Buy
966,297
+131,844
+16% +$7.51M 0.01% 1326
2020
Q4 		$58.5M Sell
834,453
-242,666
-23% -$9.97M 0.01% 978
2020
Q3 		$30.2M Buy
1,077,119
+86,229
+9% +$2.81M 0.01% 1188
2020
Q2 		$29.3M Buy
990,890
+227,068
+30% +$5.93M 0.01% 1153
2020
Q1 		$15.1M Sell
763,822
-365,722
-32% -$9.22M ﹤0.01% 1479
2019
Q4 		$33.4M Buy
1,129,544
+84,466
+8% +$2.11M 0.01% 1206
2019
Q3 		$23.8M Buy
1,045,078
+195,346
+23% +$4.84M 0.01% 1360
2019
Q2 		$21M Sell
849,732
-1,027,953
-55% -$24.5M 0.01% 1446
2019
Q1 		$45.9M Sell
1,877,685
-19,478
-1% -$441K 0.01% 897
2018
Q4 		$43.2M Buy
1,897,163
+165,195
+10% +$4.5M 0.01% 891
2018
Q3 		$55.1M Sell
1,731,968
-337,312
-16% -$10.9M 0.01% 912
2018
Q2 		$74.1M Buy
2,069,280
+186,018
+10% +$6.59M 0.02% 720
2018
Q1 		$62.4M Buy
1,883,262
+1,261,243
+203% +$44.9M 0.02% 796
2017
Q4 		$19.1M Buy
622,019
+59,083
+10% +$1.49M 0.01% 1712
2017
Q3 		$13.5M Buy
562,936
+101,236
+22% +$1.93M ﹤0.01% 1974
2017
Q2 		$7.75M Buy
461,700
+152,791
+49% +$2.75M ﹤0.01% 2421
2017
Q1 		$6.89M Buy
308,909
+100,585
+48% +$2.08M ﹤0.01% 2548
2016
Q4 		$3.38M Sell
208,324
-44,027
-17% -$668K ﹤0.01% 3401
2016
Q3 		$3.4M Sell
252,351
-46,109
-15% -$945K ﹤0.01% 3038
2016
Q2 		$7.28M Buy
298,460
+155,706
+109% +$5.25M ﹤0.01% 2250
2016
Q1 		$4.93M Buy
+142,754
New +$3.75M ﹤0.01% 2553

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Morgan Stanley's EDIT Position: Q2 2026 in Review

Morgan Stanley reduced its Editas Medicine (EDIT) stake by 17% in Q2 2026, selling an estimated $202K and leaving 342,165 shares worth $1.11M. The position accounts for ﹤0.01% of the portfolio, ranked #5164.

Morgan Stanley first reported a position in EDIT in Q1 2016 and has held it in 42 quarters since. The position peaked at $74.1M in Q2 2018. 214 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • Morgan Stanley held 342,165 shares of Editas Medicine worth $1.11M as of Q2 2026.
  • Morgan Stanley sold 69,027 Editas Medicine shares in Q2 2026, an estimated $202K.
  • Editas Medicine made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #5164 holding.
  • Morgan Stanley first reported a position in Editas Medicine in Q1 2016 and has held it in 42 quarters since.
  • Morgan Stanley's Editas Medicine position peaked at $74.1M in Q2 2018.
  • 214 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.